First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas.

Ajay K GopalRonald LevyRoch HouotSandip P PatelLeslie PopplewellCaron JacobsonXinmeng J MuShibing DengKeith A ChingYing ChenCraig B DavisBo HuangKolette D FlyAron ThallAdrian WoolfsonNancy L Bartlett

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Utomilumab in combination with rituximab demonstrated clinical activity and a favorable safety profile in patients with CD20+ NHLs.

Keyphrases

hodgkin lymphoma
endothelial cells
nk cells
growth factor
recombinant human